CeriBell, a leading healthcare technology firm, is making significant strides in revolutionizing seizure detection in acute care settings. The company's innovative point-of-care EEG platform demonstrated impressive financial performance in 2025, recording an $89 million revenue with a 36% year-over-year growth and robust 88% gross margins. Beyond its financial achievements, CeriBell is expanding its technological reach by introducing advanced algorithms for pediatric and neonatal patients, obtaining FDA clearance for delirium detection, and securing a breakthrough designation for stroke. These advancements significantly broaden the company's total addressable market, signaling substantial future growth potential within the US hospital landscape.
Scott Blumberg, Chief Financial Officer of CeriBell, detailed the company's strategic advancements and financial successes at the 47th Annual Raymond James Institutional Investors Conference. He highlighted that CeriBell's core focus remains on enhancing the diagnosis of non-convulsive seizures in critical care units and emergency departments. These seizures, often difficult to detect clinically, represent a major challenge, with 92% being non-convulsive and requiring EEG for accurate diagnosis. CeriBell's technology addresses this critical need by providing rapid, continuous EEG monitoring, a stark contrast to conventional, often resource-intensive EEG methods.
The company's commercial model is built on two primary revenue streams: a subscription-based service covering hardware and AI software, accounting for 25% of revenue with a remarkable 97% gross margin, and the sale of disposable headbands and head caps, making up the remaining 75%. This hybrid approach has enabled CeriBell to achieve 31 consecutive quarters of sequential growth, illustrating a predictable and sustainable business trajectory. Despite this growth, the company currently holds only about 3% market penetration across approximately 6,000 US hospitals equipped with ICUs or emergency departments, indicating significant untapped potential. Additionally, penetration within existing client accounts is around 30%, suggesting ample opportunity for deeper utilization.
In a strategic move to broaden its impact, CeriBell has successfully expanded its platform to include pediatric and neonatal care. This expansion, featuring new algorithms and a specialized infant head cap set for a Q2 launch, has opened up an estimated $400 million market opportunity. Blumberg emphasized the critical need for rapid seizure detection in neonates, where prolonged seizure activity can lead to permanent neurocognitive impairment. Furthermore, CeriBell secured FDA clearance for delirium detection in November 2025, a condition affecting millions of US patients annually, often leading to increased mortality and a higher risk of dementia post-discharge. The company is also progressing with its stroke initiative, having received FDA breakthrough designation in January 2026 for its novel, life-saving technology.
Addressing the challenges of adoption, Blumberg acknowledged the complexity of integrating new workflows into established hospital systems. However, he stressed that once implemented, CeriBell's systems prove sticky and difficult for competitors to displace. The company's competitive edge lies in its algorithm capabilities, extensive data, and a planned multi-indication platform approach. With $159 million in capital post-IPO and a focus on maintaining financial flexibility, CeriBell is well-positioned for sustained growth without immediate needs for additional capital. The company's long-term vision includes becoming the standard of care for acute care seizure detection and evolving EEG into a vital sign, leveraging its platform to differentiate various neurological conditions.